Cargando…

Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy

The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture for potential use in the fixed-dose combination therapy. The system was characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Skotnicki, Marcin, Jadach, Barbara, Skotnicka, Agnieszka, Milanowski, Bartłomiej, Tajber, Lidia, Pyda, Marek, Kujawski, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831949/
https://www.ncbi.nlm.nih.gov/pubmed/33477672
http://dx.doi.org/10.3390/pharmaceutics13010118
_version_ 1783641729036976128
author Skotnicki, Marcin
Jadach, Barbara
Skotnicka, Agnieszka
Milanowski, Bartłomiej
Tajber, Lidia
Pyda, Marek
Kujawski, Jacek
author_facet Skotnicki, Marcin
Jadach, Barbara
Skotnicka, Agnieszka
Milanowski, Bartłomiej
Tajber, Lidia
Pyda, Marek
Kujawski, Jacek
author_sort Skotnicki, Marcin
collection PubMed
description The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture for potential use in the fixed-dose combination therapy. The system was characterized by employing standard differential scanning calorimetry (DSC), Fourier transform-infrared spectroscopy (FT-IR), and intrinsic dissolution rate studies. Quantum mechanical calculations were performed to obtain information regarding intermolecular interactions in the studied co-amorphous ATR-IRB system. The co-amorphous formulation showed a significant improvement in the intrinsic dissolution rate (IDR) of IRB over pure crystalline as well as its amorphous counterpart. An unusual behavior was observed for ATR, as the IDR of ATR in the co-amorphous formulation was slightly lower than that of amorphous ATR alone. Short-term physical aging studies of up to 8 h proved that the ATR-IRB co-amorphous system remained in the amorphous form. Furthermore, no physical aging occurred in the co-amorphous system. FT-IR, density functional theory calculations, and analysis of T(g) value of co-amorphous system using the Couchman–Karasz equation revealed the presence of molecular interactions between APIs, which may contribute to the increased physical stability.
format Online
Article
Text
id pubmed-7831949
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78319492021-01-26 Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy Skotnicki, Marcin Jadach, Barbara Skotnicka, Agnieszka Milanowski, Bartłomiej Tajber, Lidia Pyda, Marek Kujawski, Jacek Pharmaceutics Article The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture for potential use in the fixed-dose combination therapy. The system was characterized by employing standard differential scanning calorimetry (DSC), Fourier transform-infrared spectroscopy (FT-IR), and intrinsic dissolution rate studies. Quantum mechanical calculations were performed to obtain information regarding intermolecular interactions in the studied co-amorphous ATR-IRB system. The co-amorphous formulation showed a significant improvement in the intrinsic dissolution rate (IDR) of IRB over pure crystalline as well as its amorphous counterpart. An unusual behavior was observed for ATR, as the IDR of ATR in the co-amorphous formulation was slightly lower than that of amorphous ATR alone. Short-term physical aging studies of up to 8 h proved that the ATR-IRB co-amorphous system remained in the amorphous form. Furthermore, no physical aging occurred in the co-amorphous system. FT-IR, density functional theory calculations, and analysis of T(g) value of co-amorphous system using the Couchman–Karasz equation revealed the presence of molecular interactions between APIs, which may contribute to the increased physical stability. MDPI 2021-01-18 /pmc/articles/PMC7831949/ /pubmed/33477672 http://dx.doi.org/10.3390/pharmaceutics13010118 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skotnicki, Marcin
Jadach, Barbara
Skotnicka, Agnieszka
Milanowski, Bartłomiej
Tajber, Lidia
Pyda, Marek
Kujawski, Jacek
Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title_full Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title_fullStr Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title_full_unstemmed Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title_short Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy
title_sort physicochemical characterization of a co-amorphous atorvastatin-irbesartan system with a potential application in fixed-dose combination therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831949/
https://www.ncbi.nlm.nih.gov/pubmed/33477672
http://dx.doi.org/10.3390/pharmaceutics13010118
work_keys_str_mv AT skotnickimarcin physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT jadachbarbara physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT skotnickaagnieszka physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT milanowskibartłomiej physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT tajberlidia physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT pydamarek physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy
AT kujawskijacek physicochemicalcharacterizationofacoamorphousatorvastatinirbesartansystemwithapotentialapplicationinfixeddosecombinationtherapy